Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2019 Earnings Results

Alnylam Pharmaceuticals Misses on EPS, Stock Up 4.16%

The earnings report indicates that Alnylam Pharmaceuticals is still facing challenges in profitability, as shown by the EPS miss. However, the stock rose 4.16%, likely due to investor optimism about future growth potential and management's long-term focus. The lack of revenue data and guidance may leave some investors cautious moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.83	N/A	-9.73%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the difficulties faced this quarter, particularly with EPS performance. They remain focused on their strategic goals.

Management highlighted ongoing challenges in meeting EPS expectations.

They emphasized their commitment to long-term growth despite short-term setbacks.

Alnylam Pharmaceuticals Misses on EPS, Stock Up 4.16%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on EPS, Stock Up 4.16%

Key numbers

Management commentary